<DOC>
	<DOCNO>NCT00424242</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed disodium may stop growth cancer cell block enzymes need cell growth . Studying sample cerebrospinal fluid blood patient cancer laboratory may help doctor learn pemetrexed disodium work body identify biomarkers related cancer . PURPOSE : This clinical trial study side effect well pemetrexed disodium work treat patient leptomeningeal metastasis .</brief_summary>
	<brief_title>Pemetrexed Disodium Cerebrospinal Fluid Patients With Leptomeningeal Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Determine cerebrospinal fluid ( CSF ) : plasma ratio pemetrexed disodium different IV dose level patient leptomeningeal metastasis . - Determine safety drug patient . - Determine antitumor activity drug patient . - Assess role CSF vascular endothelial growth factor YKL 40 marker response and/or prognosis patient . OUTLINE : Patients receive pemetrexed disodium IV 10 minute day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Patients undergo lumbar puncture blood collection prior therapy 30-60 minute first dose pemetrexed disodium pharmacological study . Patients Ommaya reservoirs undergo cerebrospinal fluid ( CSF ) collection baseline 0.25 , 0.50 , 1 , 2 , 4 , 6 8.0 hour pemetrexed disodium administration . CSF obtain subsequent course study treatment . CSF blood also evaluate YKL 40 vascular endothelial growth factor . After completion study therapy , patient follow every 2-3 month . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis systemic malignancy ( solid tumor hematologic malignancy ) primary CNS lymphoma leptomeningeal metastasis ( LM ) document MRI , cerebrospinal fluid , Patients may brain metastasis addition LM Patients clinically significant interstitial fluid effusion control drainage eligible PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy &gt; 2 month Creatinine clearance ≥ 45 mL/min Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Transaminases &lt; 3.0 time ULN ( 5 time ULN hepatic metastasis ) WBC &gt; 3,000/mm³ Neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 10 g/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Able undergo lumbar puncture ( i.e. , noncommunicating hydrocephalus spinal block ) Ommaya reservoir place Able take steroid , cyanocobalamin ( vitamin B12 ) , folic acid No active cancer except nonmelanoma skin cancer carcinoma situ cervix Patients prior malignancy complete remission therapy malignancy ≥ 3 year eligible No significant medical psychiatric illness would interfere study compliance PRIOR CONCURRENT THERAPY : More 2 week since prior radiotherapy recover No concurrent radiotherapy No nonsteroidal antiinflammatory drug ( NSAIDs ) acetylsalicylic acid within 2 day study treatment ( 5 day longacting NSAIDs ) No concurrent cytotoxic chemotherapy Concurrent hormonal biological therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>leptomeningeal metastasis</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>primary central nervous system Hodgkin lymphoma</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL negative</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>secondary myelofibrosis</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
</DOC>